AURORA: Analysing and understanding responses to oncological regimens with artificial intelligence
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Immunochemotherapy (ICT) is considered standard in regards to care for small-cell lung cancer (SCLC) in extensive stages, yet reliable biomarkers for treatment response remain elusive. While previous univariate analyses suggest specific peripheral lymphocyte subsets correlate with survival, the systemic immune response involves complex, multivariate interactions that require advanced analytical approaches.
Methods
This paper analysed high-dimensional flow cytometry data from 32 patients with stage IV SCLC treated with carboplatin, etoposide, and atezolizumab. Peripheral blood was analysed at baseline ( V 0 ) and longitudinally during treatment. To identify potential early predictive biomarkers and mitigate sample attrition in later cycles, we focused on baseline and measurements after two cycles of ICT ( V 1 ). We employed a rigorous machine learning framework utilising nested cross-validation, bootstrapping, and permutation-based statistical testing to evaluate eleven different regression and survival models.
Results
Under model-appropriate metrics, regressors did not generalise ( R 2 < 0); conversely, censoring- aware Random Survival Forests (RSF) successfully extracted robust prognostic signatures. Baseline immune profiles ( V 0 ) achieved a concordance index (C-index) of 0.66 ( p = 0.015), while dynamic changes from V 0 to V 1 ( ΔV ) achieved a C-index of 0.65 ( p = 0.022). Crucially, absolute values measured after two cycles of ICT ( V 1 ) yielded no significant signal ( p = 0.445). Feature importance analysis confirmed the prognostic value of Th17 normalisation and identified Naive Regulatory T cells and Memory B cells as candidate components.
Conclusion
Machine learning validation confirms a predictive signal in the peripheral immune profile of SCLC patients. Early dynamic shifts in the balance between regulatory and effector immune arms are associated with prognosis, contrasting with the lack of signal in absolute counts after two cycles of ICT. These findings establish a proof of concept for multivariate liquid biopsy immune profiling, warranting confirmation in larger cohorts and highlighting the necessity of integrating systemic and tumour-intrinsic data.
